HC Wainwright Has Weak Forecast for ImmunityBio Q1 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – Equities researchers at HC Wainwright lowered their Q1 2026 earnings per share estimates for shares of ImmunityBio in a research report issued on Monday, February 23rd. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.09) per share for the quarter, down from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.60 EPS, FY2029 earnings at $0.89 EPS and FY2030 earnings at $1.36 EPS.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter.

A number of other equities research analysts have also issued reports on the company. Jefferies Financial Group increased their price target on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Piper Sandler upped their price objective on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a report on Monday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a report on Monday. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.60.

ImmunityBio Price Performance

Shares of IBRX stock opened at $9.54 on Wednesday. ImmunityBio has a one year low of $1.83 and a one year high of $12.43. The company’s fifty day moving average price is $4.97 and its 200-day moving average price is $3.28. The company has a market capitalization of $9.81 billion, a price-to-earnings ratio of -25.11 and a beta of 0.16.

Institutional Investors Weigh In On ImmunityBio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in ImmunityBio by 18.5% during the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock valued at $64,899,000 after purchasing an additional 5,122,052 shares during the period. State Street Corp raised its stake in ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after buying an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC raised its stake in ImmunityBio by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after buying an additional 1,030,113 shares in the last quarter. Armistice Capital LLC purchased a new stake in ImmunityBio during the second quarter worth $20,497,000. Finally, Heights Capital Management Inc. bought a new stake in ImmunityBio during the 3rd quarter valued at $16,152,000. Institutional investors own 8.58% of the company’s stock.

Insider Transactions at ImmunityBio

In related news, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christobel Selecky sold 50,000 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 426,967 shares of company stock valued at $3,565,662. 69.48% of the stock is owned by insiders.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial adoption drove a multi‑hundred percent revenue increase, the headline catalyst for the recent rally — investors are treating this as evidence sales are scaling. Read More.
• Positive Sentiment: Multiple outlets report ~600–700% YoY revenue growth attributed to ANKTIVA uptake, reinforcing momentum and driving buying interest. Read More.
• Positive Sentiment: Regulatory/approval expansions and new commercial partnerships for ANKTIVA broaden the company’s global market opportunity—supports multi‑region revenue upside. Read More.
• Positive Sentiment: Q4 results beat consensus (smaller EPS loss and stronger revenue), which validated the commercial story in the near term and triggered bullish analyst notes. Read More.
• Neutral Sentiment: Analysis pieces highlight a disconnect between clinical progress, long‑term fundamentals and extreme short‑term price moves — useful context for risk/reward but not an immediate catalyst. Read More.
• Neutral Sentiment: Analysts (including HC Wainwright) kept bullish long‑term targets while adjusting near‑term EPS — supports a multi‑year upside thesis but adds short‑term uncertainty. Read More.
• Negative Sentiment: Insider selling: Director Barry J. Simon and others sold significant blocks in recent days, which can signal profit‑taking and weigh on sentiment. Read More.
• Negative Sentiment: Company remains unprofitable and consensus still forecasts a net loss for the current year — valuation and execution risks remain if commercial growth stalls. Read More.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.